# Which twenty-one sources can answer your study questions?

> Which papers can you use to check the claims? — Research Peptide Fundamentals research peptides: Match claims to papers. Ask whether tests involved people or animals and what changed.

**PAPERS / CHECK THE FINDINGS**

A claim about hunger or healing needs evidence you can check. These papers include patient trials, reviews of earlier papers, animal tests, and cells grown in dishes.

## What do the paper numbers and study labels mean?

Match the small number beside a claim to the paper below. Tirzepatide uses 1–7, semaglutide 8–11, Thymosin Alpha-1 12–16, and BPC-157 17–21. Original titles accompany a link to each paper.

A number guides you like a newspaper's page number.

A review examines earlier papers. The reviewers aren't treating new patients. A systematic review searches for papers using stated rules.

A meta-analysis combines their results to judge the overall difference. A narrative review describes papers without that combined calculation.

Efficacy asks whether treatment helped. Clinical work involves people. Controlled trials compare treatments.

A pilot study starts with a small group to see what happens. For your questions, read each peptide’s findings about patients and remaining doubts.

## References

[1] Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40353578/
[2] Farzam K, Patel P. Tirzepatide (StatPearls). StatPearls [Internet], NCBI Bookshelf. 2024. https://www.ncbi.nlm.nih.gov/books/NBK585056/
[3] Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. https://pubmed.ncbi.nlm.nih.gov/37908750/
[4] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/
[5] Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/34170647/
[6] Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. https://pubmed.ncbi.nlm.nih.gov/32730231/
[7] Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/30473097/
[8] Perkovic V, et al. (FLOW Trial Committees and Investigators). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. https://pubmed.ncbi.nlm.nih.gov/38785209/
[9] Lincoff AM, et al. (SELECT Trial Investigators). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. https://pubmed.ncbi.nlm.nih.gov/37952131/
[10] Wilding JPH, et al. (STEP 1 Study Group). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
[11] Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. https://pubmed.ncbi.nlm.nih.gov/34305810/
[12] Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025. https://pubmed.ncbi.nlm.nih.gov/39814420/
[13] Dominari A, Hathaway Iii D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020. https://pubmed.ncbi.nlm.nih.gov/33362999/
[14] Liu Y, Pan Y, Hu Z, et al. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis. 2020. https://pubmed.ncbi.nlm.nih.gov/32442287/
[15] Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019. https://pubmed.ncbi.nlm.nih.gov/31555601/
[16] Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013. https://pubmed.ncbi.nlm.nih.gov/23327199/
[17] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40131143/
[18] McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[19] He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. https://pubmed.ncbi.nlm.nih.gov/36588717/
[20] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[21] Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10:1032-1037. https://pubmed.ncbi.nlm.nih.gov/15052688/

---

Peptides National is an independent digest of peptide evidence and jurisdiction-specific policy categories, not a clinic, dispensary, or source of medical advice.